In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neuromedical Systems, Inc.

Latest From Neuromedical Systems, Inc.

A Buyer's Market in Diagnostics

Deal activity in diagnostics has been way down in 1999 and while a few strategically sound deals are getting done, the scale has been very small. With financing and M&A options drying up, smaller diagnostics companies are more squeezed than ever. A plucky few have snared good deals. Here's how.

Medical Device Strategy

Demise of a Wall Street Star

Neuromedical Systems, once a rising star on Wall Street and the leader of a crop of new Pap smear automation companies, filed for bankruptcy in March. One of its chief competitors, AutoCyte Inc. is bidding to buy the company's intellectual property. AutoCyte then has an agreement with NeoPath Inc. to share ownership of the assets and in turn Neopath will pay approximately half of the purchase price of about $12 million to AutoCyte. The AutoCyte deal has to be approved by the US bankruptcy court.

Medical Device Strategy

Another New Approach to Cytology

The founder and former CEO of AccuMed International Inc., Peter Gombrich, has started a new company based on licensing and acquisitions in the fields of cytology and urology. He is using an innovative financing strategy that merges the privately held InPath LLC into Bell National Corp., a publically traded shell company. This allows Inpath to obtain cash and offer investors an exit, despite the coolness of public markets to small cap stocks.

Medical Device Strategy

Progress in Cervical Cancer Screening

The smoke from the Pap wars is beginning to clear as Cytyc, which sells the {ThinPrep} monolayer system for screening for cervical cancer pushes ahead and NeoPath gets FDA approval to sell its automated instrument as a primary reader of Pap smears. Cytyc is doing quite well in its battle to get attractive reimbursement for its sample prep method. More problematic is NeuroMed Systems, which is struggling to maintain the interest of laboratories in its device which helps pathologists pinpoint trouble spots on Pap smears.

Medical Device Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
  • Medical Devices
    • Diagnostic Equipment & Supplies